您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>骨头疾病治疗

2015-2020年全球风湿性关节炎技术市场研究报告
Therapies for Rheumatoid Arthritis: Technologies and Global Markets

2015-2020年全球风湿性关节炎技术市场研究报告
【报告编号】:No.25888
【发布时间】:2016-07
【关 键 字】:Rheumatoid Arthritis    风湿性关节炎       
【报告页数】:93页
【报告价格】:电子版:6650美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 骨头疾病治疗行业的相关报告
DESCRIPTION
 
The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.
 
This report provides:
An overview of the global markets, therapies, and related technologies for treating Rheumatoid Arthritis (RA).
Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
Discussion covering suppliers of therapeutic products for RA and analysis based on market share, product types, and geography (where data is available).
An overview of the disease including etiology, epidemiology, pathophysiology, risk factors and co-morbidities, and progression and outcomes.
An in-depth pipeline analysis, and biologic agents, both anti -TNF and non-TNF related currently under investigation or newly approved for use by the FDA are highlighted.
Relevant patent analysis.
Profiles of major players in the industry.
 
 
REPORT SCOPE
 
SCOPE OF REPORT
The emphasis of this report is on the marketed products and also products in different stages of clinical development.
 
Special focus is placed on how new products and technologies will affect current market leaders in the RA treatment sector. Profiles are provided of companies projected to have products in the market during the forecast period and on companies with promising pipelines.
 
Profiles of the many emerging competitors in this sector provide a comprehensive assessment of the various products and technologies entering this market as well as marketing strategies being used to gain a competitive edge.
 
Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the rheumatoid arthritis market. The key players are J&J, AbbVie, Pfizer, GSK, Eli Lilly, Diachii Sankyo, Bristol-Myers Squibb (BMS), Roche, etc.
 
ANALYST'S CREDENTIALS
Geeta Ogra Bedi has more than 17 years of global experience in the pharmaceutical and healthcare industries and is the Founder/Director of Providentia Research, a consulting firm that provides services in the area of auditing (PVG, GCP, GLP and GMP), medical writing and market research. She has worked with a variety of organizations internationally, ranging from contract research organizations and business partners to clinical sites, service providers and manufacturers. She led the quality assurance program for the directed studies and clinical development of an antimalarial is Asia and Africa. Geeta received an Appreciation Award from the President of India for exceptional contribution in the development of a new chemical entity (NCE), as well as an award for best poster at an international conference on Hypertension and Diabetes. She received her Bachelor's degree in Pharmacy and her Master's in Pharmacy/Pharmacology in New Delhi, India.
 
TABLE OF CONTENTS
 
CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF REPORT
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
 
CHAPTER 2 SUMMARY
SUMMARY TABLE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS, BY THERAPEUTIC CLASS, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS BY THERAPEUTIC CLASS, 2014-2020 ($ MILLIONS)
SUMMARY TABLE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, 2014-2020 ($ MILLIONS)
 
CHAPTER 3 DISEASE OVERVIEW
ETIOLOGY
PATHOPHYSIOLOGY
SYMPTOMS
TABLE 1 COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
PROGNOSIS
QUALITY OF LIFE
EPIDEMIOLOGY
DISEASE BACKGROUND
TABLE 2 EPIDEMIOLOGICAL FORECAST FOR DIAGNOSED PREVALENT CASES OF RHEUMATOID ARTHRITIS, BY REGION, THROUGH 2020 (NO.)
RISK FACTORS AND COMORBIDITIES
TABLE 3 RISK FACTORS AND COMORBIDITIES FOR RHEUMATOID ARTHRITIS
 
CHAPTER 4 DISEASE MANAGEMENT
DIAGNOSIS
1987 ACR RA DIAGNOSTIC CRITERIA
TABLE 4 THE 1987 ACR DIAGNOSTIC CRITERIA FOR RA
2010 ACR/EULAR RA DIAGNOSTIC CRITERIA
TABLE 5 THE 2010 ACR/EULAR DIAGNOSTIC CRITERIA FOR RA
TREATMENT OVERVIEW
TABLE 6 TREATMENT GUIDELINES FOR RA
ACR 2012 RECOMMENDATIONS FOR THE TREATMENT OF RA
TABLE 7 THE ACR 2012 CRITERIA FOR RA REMISSION, AND LOW, MODERATE, AND HIGH DISEASE ACTIVITY
TABLE 8 THE ACR/EULAR 2011 CRITERIA FOR RA REMISSION USED IN THE 2013 UPDATE TO THE EULAR RECOMMENDATIONS FOR RA MANAGEMENT
FIGURE 1 FLOWCHART FOR THE MANAGEMENT OF RA IN EARLY DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
FIGURE 2 FLOWCHART FOR THE MANAGEMENT OF RA IN ESTABLISHED DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
2015 ACR GUIDELINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
RECOMMENDATIONS FOR THE TREATMENT OF PATIENTS WITH EARLY RA
TABLE 9 RECOMMENDATIONS FOR PATIENTS WITH SYMPTOMATIC EARLY RA
FIGURE 3 RECOMMENDATIONS FOR TREATMENT OF EARLY RA
RECOMMENDATIONS FOR THE TREATMENT OF PATIENTS WITH ESTABLISHED RA
TABLE 10 RECOMMENDATIONS FOR OPTIMAL FOLLOWUP LABORATORY MONITORING INTERVALS*
RECOMMENDATIONS FOR LABORATORY MONITORING FOR DMARDS AND TB SCREENING IN PATIENTS RECEIVING BIOLOGICS OR TOFACITINIB
EULAR 2013 RECOMMENDATIONS FOR THE TREATMENT OF RA
FIGURE 4 FLOWCHART FOR THE MANAGEMENT OF PATIENTS WITH RA, ACCORDING TO THE 2013 EULAR RECOMMENDATIONS
TABLE 11 MOSTMOST PRESCRIBED BIOLOGICS FOR THE TREATMENT OF RA (AFTER CSDMARDS), BY REGION
TABLE 12 MINOR THERAPEUTIC DRUG CLASSES USED TO TREAT RA
CLINICAL PRACTICE
TABLE 13 RA DIAGNOSIS PROFILE IN THE U.S.
France
TABLE 14 RA DIAGNOSIS PROFILE IN FRANCE
Germany
TABLE 15 RA DIAGNOSIS PROFILE IN GERMANY
Italy
TABLE 16 RA DIAGNOSIS PROFILE IN ITALY
Spain
TABLE 17 RA DIAGNOSIS PROFILE IN SPAIN
U.K.
TABLE 18 RA DIAGNOSIS PROFILE IN THE UK
Japan
TABLE 19 RA DIAGNOSIS PROFILE IN JAPAN
Australia
TABLE 20 RA DIAGNOSIS PROFILE IN AUSTRALIA
China
TABLE 21 RA DIAGNOSIS PROFILE IN CHINA
India
TABLE 22 RA DIAGNOSIS PROFILE IN INDIA
TABLE 23 LEADING DRUGS FOR TREATMENT OF RA
BIOSIMILARS
TABLE 24 GLOBAL MARKET FOR MAJOR BIOSIMILARS BY REGION AND TYPE, THROUGH 2020 ($ MILLIONS)
TABLE 25 GLOBAL MARKET FOR ENBREL, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 26 GLOBAL MARKET FOR HUMIRA, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 27 GLOBAL MARKET FOR REMICADE (INFLIXIMAB), BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 28 GLOBAL MARKET FOR ACTEMRA, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 29 GLOBAL MARKET FOR ORENCIA (ABATACEPT), BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 30 GLOBAL MARKET FOR RITUXAN (MABTHERA), BY REGION, THROUGH 2020 ($ MILLIONS)
COMPETITIVE ASSESSMENT
OVERVIEW
 
CHAPTER 5 UNMET NEED AND OPPORTUNITY
UNMET NEED
GAP ANALYSIS
OPPORTUNITY
 
CHAPTER 6 PIPELINE ASSESSMENT
OVERVIEW 6
TABLE 31 LIST OF RA THERAPIES IN CLINICAL TRIALS, BY PHASE
TABLE 32 LIST OF RA THERAPIES IN DEVELOPMENT, BY PHASE
 
CHAPTER 7 PATENT ASSESSMENTS
TABLE 33 LIST OF THERAPIES FOR RA IN THE MARKET, BY PATENT EXPIRY DATE
TABLE 34 LIST OF PATENTS ISSUED FOR RA THERAPIES
TABLE 35 LIST OF PATENT APPLICATIONS FOR RA THERAPIES
 
CHAPTER 8 COMPANY PROFILES
AB SCIENCE
ABBOTT LABORATORIES
ABBVIE
AMGEN INC.
ASTELLAS
BAXALTA INC.
BRISTOL-MYERS SQUIBB
BOEHRINGER INGELHEIM
CELGENE CORP.
CELLTRION INC.
COHERUS BIOSCIENCES INC.
DAIICHI SANKYO CO. LTD.
EISAI
ELI LILLY
FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD.
GLAXOSMITHKLINE
INCYTE CORP.
JOHNSON & JOHNSON
KINETA INC.
MABTECH AB
MYCENAX BIOTECH INC.
NOVARTIS AG
ONO PHARMACEUTICAL CO. LTD.
PFIZER
ROCHE
SAMSUNG BIOLOGICS CO. LTD.
TAKEDA PHARMACEUTICALS
UCB GROUP/IMMUNOMEDICS
 
CHAPTER 9 DRIVERS AND BARRIERS
TABLE 36 DRIVERS AND BARRIERS FOR RA THERAPIES
DRIVER: LAUNCH OF NOVEL DRUGS, INCLUDING ORAL JAK INHIBITORS AND NOVEL BIOLOGICS FOR RA
DRIVER: EARLIER DIAGNOSIS AND TREATMENT
DRIVER: MARKET ENTRY OF BIOSIMILARS WILL BRING A THERAPY OPTION FOR THOSE WHO CANNOT AFFORD BRANDED BIOLOGICS
DRIVER: AGING POPULATION AND INCREASING PREVALENT CASES OF RA
BARRIER: EFFORTS TO REDUCE COSTS IN THE TREATMENT OF RA
BARRIER: LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
BARRIER: ENTRY OF BIOSIMILARS WILL CREATE A LESS EXPENSIVE TREATMENT ALTERNATIVE
 
LIST OF TABLES
SUMMARY TABLE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS, BY THERAPEUTIC CLASS, THROUGH 2020 ($ MILLIONS)
SUMMARY TABLE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 1 COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
TABLE 2 EPIDEMIOLOGICAL FORECAST FOR DIAGNOSED PREVALENT CASES OF RHEUMATOID ARTHRITIS, BY REGION, THROUGH 2020 (NO.)
TABLE 3 RISK FACTORS AND COMORBIDITIES FOR RHEUMATOID ARTHRITIS
TABLE 4 THE 1987 ACR DIAGNOSTIC CRITERIA FOR RA
TABLE 5 THE 2010 ACR/EULAR DIAGNOSTIC CRITERIA FOR RA
TABLE 6 TREATMENT GUIDELINES FOR RA
TABLE 7 THE ACR 2012 CRITERIA FOR RA REMISSION, AND LOW, MODERATE, AND HIGH DISEASE ACTIVITY
TABLE 8 THE ACR/EULAR 2011 CRITERIA FOR RA REMISSION USED IN THE 2013 UPDATE TO THE EULAR RECOMMENDATIONS FOR RA MANAGEMENT
TABLE 9 RECOMMENDATIONS FOR PATIENTS WITH SYMPTOMATIC EARLY RA
TABLE 10 RECOMMENDATIONS FOR OPTIMAL FOLLOWUP LABORATORY MONITORING INTERVALS*
TABLE 11 MOSTMOST PRESCRIBED BIOLOGICS FOR THE TREATMENT OF RA (AFTER CSDMARDS), BY REGION
TABLE 12 MINOR THERAPEUTIC DRUG CLASSES USED TO TREAT RA
TABLE 13 RA DIAGNOSIS PROFILE IN THE U.S.
TABLE 14 RA DIAGNOSIS PROFILE IN FRANCE
TABLE 15 RA DIAGNOSIS PROFILE IN GERMANY
TABLE 16 RA DIAGNOSIS PROFILE IN ITALY
TABLE 17 RA DIAGNOSIS PROFILE IN SPAIN
TABLE 18 RA DIAGNOSIS PROFILE IN THE UK
TABLE 19 RA DIAGNOSIS PROFILE IN JAPAN
TABLE 20 RA DIAGNOSIS PROFILE IN AUSTRALIA
TABLE 21 RA DIAGNOSIS PROFILE IN CHINA
TABLE 22 RA DIAGNOSIS PROFILE IN INDIA
TABLE 23 LEADING DRUGS FOR TREATMENT OF RA
TABLE 24 GLOBAL MARKET FOR MAJOR BIOSIMILARS BY REGION AND TYPE, THROUGH 2020 ($ MILLIONS)
TABLE 25 GLOBAL MARKET FOR ENBREL, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 26 GLOBAL MARKET FOR HUMIRA, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 27 GLOBAL MARKET FOR REMICADE (INFLIXIMAB), BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 28 GLOBAL MARKET FOR ACTEMRA, BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 29 GLOBAL MARKET FOR ORENCIA (ABATACEPT), BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 30 GLOBAL MARKET FOR RITUXAN (MABTHERA), BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 31 LIST OF RA THERAPIES IN CLINICAL TRIALS, BY PHASE
TABLE 32 LIST OF RA THERAPIES IN DEVELOPMENT, BY PHASE
TABLE 33 LIST OF THERAPIES FOR RA IN THE MARKET, BY PATENT EXPIRY DATE
TABLE 34 LIST OF PATENTS ISSUED FOR RA THERAPIES
TABLE 35 LIST OF PATENT APPLICATIONS FOR RA THERAPIES
TABLE 36 DRIVERS AND BARRIERS FOR RA THERAPIES
 
LIST OF FIGURES
SUMMARY FIGURE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS BY THERAPEUTIC CLASS, 2014-2020 ($ MILLIONS)
SUMMARY FIGURE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, 2014-2020 ($ MILLIONS)
FIGURE 1 FLOWCHART FOR THE MANAGEMENT OF RA IN EARLY DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
FIGURE 2 FLOWCHART FOR THE MANAGEMENT OF RA IN ESTABLISHED DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
FIGURE 3 RECOMMENDATIONS FOR TREATMENT OF EARLY RA
FIGURE 4 FLOWCHART FOR THE MANAGEMENT OF PATIENTS WITH RA, ACCORDING TO THE 2013 EULAR RECOMMENDATIONS

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统